263 related articles for article (PubMed ID: 34740610)
21. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
22. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
J Nucl Med; 2024 May; ():. PubMed ID: 38782457
[TBL] [Abstract][Full Text] [Related]
23. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract][Full Text] [Related]
24. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
25. ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
Res Sq; 2023 Dec; ():. PubMed ID: 38196594
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
27. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
[TBL] [Abstract][Full Text] [Related]
28. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Persse T; Galipeau P; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
NPJ Precis Oncol; 2024 May; 8(1):104. PubMed ID: 38760413
[TBL] [Abstract][Full Text] [Related]
29. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
[TBL] [Abstract][Full Text] [Related]
30. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
[TBL] [Abstract][Full Text] [Related]
31. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
32. A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
Zheng C; Feng J; Lu D; Wang P; Xing S; Coll JL; Yang D; Yan X
PLoS One; 2011; 6(6):e21146. PubMed ID: 21731662
[TBL] [Abstract][Full Text] [Related]
33. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
34. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
35. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
[TBL] [Abstract][Full Text] [Related]
36. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
[TBL] [Abstract][Full Text] [Related]
37. Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.
Gu S; Zaidi S; Hassan MI; Mohammad T; Malta TM; Noushmehr H; Nguyen B; Crandall KA; Srivastav J; Obias V; Lin P; Nguyen BN; Yao M; Yao R; King CH; Mazumder R; Mishra B; Rao S; Mishra L
Gastroenterology; 2020 Jan; 158(1):238-252. PubMed ID: 31585122
[TBL] [Abstract][Full Text] [Related]
38. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
39. [Current Trend of CAR-T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer].
Takahashi S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1038-1042. PubMed ID: 38035830
[TBL] [Abstract][Full Text] [Related]
40. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
